{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Best Overall Confirmed Complete Response"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Best Overall Confirmed Partial Response"},{"measurements":[{"groupId":"OG000","value":"16"}],"title":"Best Overall Stable Disease"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Best Overall Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Best ORR was assessed by Independent Radiology Review using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria. Best overall response was the best response recorded from the start of the study treatment until the end of treatment taking into account the requirement for confirmation.\n\nPer RECIST v1.1, best overall response assignment depended on the findings of both target and non-target disease and also took into consideration the appearance of new lesions. Overall response rate was defined as the percentage of patients who achieve a confirmed PR or CR per RECIST 1.1. At each timepoint, objective tumor response for target lesions were assessed as such: Complete Response (CR), disappearance of all target lesions, and pathological lymph nodes must have a reduction \\<10 mm; Partial Response (PR), ≥30% decrease in the sum of the longest diameter of target lesions.","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"OG000","title":"Nab-Sirolimus"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy Evaluable Patient Population","reportingStatus":"POSTED","timeFrame":"through study completion (up to 72 months)","title":"Objective Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}